4-[(4-quinolinylyl)oxymethyl]aniline | 747396-77-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-[(4-quinolinylyl)oxymethyl]aniline
• 英文别名: 4-(Quinolin-4-yloxymethyl)aniline
• CAS: 747396-77-6
• 化学式: C₁₆H₁₄N₂O
• 分子量: 250.3
• InChiKey: PKFIELLUGINZDF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[(4-quinolinylyl)oxymethyl]aniline 在 盐酸羟胺 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (1S,2S)-Cyclopentane-1,2-dicarboxylic acid 1-hydroxyamide 2-{[4-(quinolin-4-yloxymethyl)-phenyl]-amide}
  参考文献：
  名称：

  Rational design, synthesis and structure–Activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 1: lead identification

  摘要：

  Rational design based on the broad spectrum MMP inhibitor CGS 27023A led to the identification of a novel series of cyclic succinate TACE inhibitors. As a mixture of two enantiomers, the lead compound 17b exhibited potent enzyme activity (IC50 = 8 nM) in the inhibition of porcine TNF-alpha converting enzyme (pTACE) and excellent selectivity over aggrecanase and MMP-1, -2 and -9. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.056
• 作为产物：
  描述：

  4-((tert-butoxycarbonyl)amino)benzyl methanesulfonate 在 盐酸 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-[(4-quinolinylyl)oxymethyl]aniline
  参考文献：
  名称：

  Rational design, synthesis and structure–Activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 1: lead identification

  摘要：

  Rational design based on the broad spectrum MMP inhibitor CGS 27023A led to the identification of a novel series of cyclic succinate TACE inhibitors. As a mixture of two enantiomers, the lead compound 17b exhibited potent enzyme activity (IC50 = 8 nM) in the inhibition of porcine TNF-alpha converting enzyme (pTACE) and excellent selectivity over aggrecanase and MMP-1, -2 and -9. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.056

文献信息

• Rational design, synthesis and structure–activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 2: lead optimization
  作者：Chu-Biao Xue、Xiaohua He、John Roderick、Ronald L Corbett、James J.-W Duan、Rui-Qin Liu、Maryanne B Covington、Mingxin Qian、Maria D Ribadeneira、Krishna Vaddi、David D Christ、Robert C Newton、James M Trzaskos、Ronald L Magolda、Ruth R Wexler、Carl P Decicco

  DOI：10.1016/j.bmcl.2003.09.057

  日期：2003.12

  Modifications of the lead TACE inhibitor 1 (N-hydroxy-trans-2-[4-(4-quinolinyloxymethyl)anilinyl]carbonyl}-1-cyclo-hexanecarboxamide) at the cyclohexyl ring and the quinoline moiety led to the identification of a series of piperidine containing TACE inhibitors with potent activity in the inhibition of TNF-alpha release in the whole blood assay (WBA). The most potent analogue IM491 [N-hydroxy-(5S,6S)-1-methyl-6-[4-(2-methyl-4-quinolinylmethoxy)anilinyl]carbonyl}-5-piperidinecarboxamide] exhibited an IC50 value of 20 nM in WBA with excellent selectivity over MMP-1, -2 and -9 and is orally bioavailable with an F value of 43% in beagle dogs. (C) 2003 Elsevier Ltd. All rights reserved.